CD19 CART Cells for Patients With Relapse and Refractory CD19+ B-cell Lymphoma.

Inclusion Criteria: * 1\. 18 years to 70 years, expected survival \> 3 months; * 2\. CD19 positive B-cell lymphoma; * 3\. KPS \>80; * 4\. Having at least one measurable lesions; * 5\. Cardiac function: 1-2 levels; Liver: TBIL≤3ULN，AST ≤2.5ULN，ALT ≤2.5ULN; kidney: Cr≤1.25ULN; bone marrow: WBC ≥ 3.0×109/L, Hb ≥90 g/L, PLT ≥ 80×109/L）; * 6\. No serious allergic constitution; * 7\. No other serous diseases that conflicts with the clinical program; * 8\. No other cancer history; * 9\. No serious mental disorder; * 10\. Informed consent is signed by a subject or his lineal relation. Exclusion Criteria: * 1\. Pregnant or lactating women; (female participants of reproductive potential must have a negative serum or urine pregnancy test); * 2\. Uncontrolled active infection, HIV infection, syphilis serology reaction positive; * 3\. Active hepatitis B or hepatitis C infection; * 4\. Recent or current use of glucocorticoid or other immunosuppressor; * 5\. With severe cardiac, liver, renal insufficiency, diabetes and other diseases; * 6\. Transaminase \>2.5ULN, Bilirubin \>3ULN，Creatinine\>1.25ULN * 7\. Participate in other clinical research in the past three months; previously treatment with any gene therapy products; * 8\. Researchers think of that does not fit to participate in the study, or other cases that affect the clinical trial results;